Thromboembolic Disease clinical trials

Explore recruiting thromboembolic disease clinical trials.

Recruiting thromboembolic disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Thromboembolic Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty

Lithuania, Latvia, Poland, Hungary, Bulgaria, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)

Bulgaria, Poland, Hungary, Latvia, Lithuania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX).

Bulgaria, Lithuania, Poland, Hungary, Latvia, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prophylaxis of venous thromboembolic disease with LMWH (TINzaparin) in patients with metastatic colorectal cancer who start the first line of treatment.

Spain, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

API-AHAI - Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Anticoagulant medicines for Balloon Pulmonary Angioplasty

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Thromboembolic Disease trials by city

Thromboembolic Disease in Toronto Thromboembolic Disease in Vancouver Thromboembolic Disease in Montreal Thromboembolic Disease in Calgary Thromboembolic Disease in Edmonton Thromboembolic Disease in Ottawa Thromboembolic Disease in Winnipeg Thromboembolic Disease in Quebec City Thromboembolic Disease in Hamilton Thromboembolic Disease in Kitchener Thromboembolic Disease in London Thromboembolic Disease in Halifax Thromboembolic Disease in New York Thromboembolic Disease in Los Angeles Thromboembolic Disease in Chicago Thromboembolic Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease